Developing first-in-class cardiovascular biopharmaceuticals
that target natural repair pathways
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept into Phase II clinical trials for heart failure and critical limb ischemia. The company's lead product, JVS-100, is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival, recruiting endogenous stem cells to the damaged region, and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential.